Armata Pharmaceuticals Inc ARMP:NYSE American

Last Price$4.22AMEX Previous Close - Last Trade as of 8:00PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$3.00 (5)
Ask (Size)$5.11 (1)
Day Low / HighN/A - N/A

View Biotechnology IndustryPeer Comparison as of 08/12/2022


Armata Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $4.22
Change: -0.03 (0.71%)
Volume: 222.00
8:00PM ET 8/12/2022

Co-Diagnostics Inc ( NASDAQ )

Price: $4.48
Change: -1.98 (30.65%)
Volume: 4.1 M
4:00PM ET 8/12/2022

La Jolla Pharmaceutical Co ( NASDAQ )

Price: $6.21
Change: +0.01 (0.16%)
Volume: 62.4 K
4:00PM ET 8/12/2022

DarioHealth Corp ( NASDAQ )

Price: $7.16
Change: +0.17 (2.43%)
Volume: 535.6 K
4:00PM ET 8/12/2022

Enochian Biosciences Inc ( NASDAQ )

Price: $2.77
Change: +0.10 (3.75%)
Volume: 63.1 K
4:00PM ET 8/12/2022

Read more news Recent News

Armata Pharmaceuticals Says FDA Clears Application for Initial-stage Trial of Investigational Prosthetic Joint Infection Treatment
11:02AM ET 8/01/2022 MT Newswires

Armata Pharmaceuticals (ARMP) said Monday the US Food and Drug Administration has cleared an Investigational New Drug Application for AP-SA02 for treatment...

Armata Pharmaceuticals Says First Patient Dosed in Early Trial of AP-SA02 to Treat Bloodstream Infections
10:06AM ET 5/23/2022 MT Newswires

Armata Pharmaceuticals (ARMP) said Monday it has dosed the first person in the phase 1b/2a clinical trial of AP-SA02 to treat complicated Staphylococcus...

Armata Pharmaceuticals Files Shelf on Behalf of Certain Selling Stocholders
4:15AM ET 3/30/2022 MT Newswires

Armata Pharmaceuticals (ARMP) filed a registration statement with the US Securities and Exchange Commission on behalf of certain shareholders for the...

Armata Pharmaceuticals Gets US FDA Clearance for Non-Cystic Fibrosis Bronchiectasis Treatment Clinical Trial
12:00PM ET 2/22/2022 MT Newswires

Armata Pharmaceuticals (ARMP) said Tuesday the US Food and Drug Administration has cleared its investigational drug application to launch a clinical trial...

View all Commentary and Analysis

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates
4:45PM ET 8/11/2022 Zacks

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%,...

The Best Of Backtesting - Week Oct. 4
10:20AM ET 10/09/2021 Seeking Alpha

BiomX: Undervalued With Multiple Upcoming Catalysts
6:42PM ET 10/06/2021 Seeking Alpha

The Best Of Backtesting - Week Aug. 30
3:51PM ET 9/02/2021 Seeking Alpha

Company Profile

Business DescriptionArmata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA. View company web site for more details
Address4503 Glencoe Avenue
Los Angeles, California 90292
Number of Employees31
Recent SEC Filing08/11/20228-K
Chief Executive Officer & DirectorBrian C. Varnum
Vice President-OperationsDuane A. Morris
Chief Financial & Accounting OfficerErin Butler
Vice President-Clinical DevelopmentMina Pastagia

Company Highlights

Price Open$4.22
Previous Close$4.25
52 Week Range$2.82 - 6.49
Market Capitalization$152.5 M
Shares Outstanding36.1 M
SectorHealth Technology
Next Earnings Announcement11/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.03
Beta vs. S&P 500N/A
Net Profit Margin-549.64%
Return on Equity-71.85%

Analyst Ratings as of 05/29/2022

Consensus RecommendationConsensus Icon
Powered by Factset